582 reports of this reaction
3.8% of all RANOLAZINE reports
#5 most reported adverse reaction
STENT PLACEMENT is the #5 most commonly reported adverse reaction for RANOLAZINE, manufactured by A2A Integrated Pharmaceuticals. There are 582 FDA adverse event reports linking RANOLAZINE to STENT PLACEMENT. This represents approximately 3.8% of all 15,363 adverse event reports for this drug.
Patients taking RANOLAZINE who experience stent placement should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
STENT PLACEMENT is moderately reported among RANOLAZINE users, representing a notable but not dominant share of adverse events.
In addition to stent placement, the following adverse reactions have been reported for RANOLAZINE:
STENT PLACEMENT has been reported as an adverse event in 582 FDA reports for RANOLAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
STENT PLACEMENT accounts for approximately 3.8% of all adverse event reports for RANOLAZINE, making it a notable side effect.
If you experience stent placement while taking RANOLAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.